Gucci Q2
This article was originally published in The Rose Sheet
Executive Summary
Yves Saint Laurent fragrance and cosmetics sales increased 5.7% on constant currency basis for fiscal second quarter ended July 31, Gucci announces in 1sales and earnings report Sept. 26. Sales were fueled by strong growth of Opium, which saw a 23.6% increase in sales during the period, company adds. Despite strength of Yves Saint Laurent, YSL Beauté consolidated sales fell 3.8% during the quarter to $104.4 mil. (€1=$.98). Beauty division still on track to achieve high single-digit revenue growth and operating margin before goodwill and trademark amortization of approximately 7%, Gucci maintains...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.